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1. Introduction 
In 1977, Reddy and Kumer reported the prolifera- 
tion of M, 80 000 polypeptide in clofibrate-treated 
rat liver and suggested that this polypeptide might be 
a protein component of peroxisomes [ 11. This finding 
is significant for studies of the biogenesis and turn- 
over of hepatic peroxisomes because no other protein 
component is available as a marker of the peroxisomal 
membrane. In addition, studies of the physiological 
role of rat liver peroxisomes during the last few years, 
have shown that the peroxisomes contain enzymes 
capable of catalysing P-oxidation of long chain fatty 
acids, as well as catalase, carnitine acetyltransferase 
and several H,Oz-generating oxidases [2-61. Enoyl- 
CoA hydratase, one of the enzymes of fatty acid 
oxidizing system has been purified [7] from hepatic 
peroxisomes and from the iV, of the purified enzyme 
suggested that the peroxisome-associated polypeptide 
ofM, 80 000 first reported in [I] in clofibrate treated 
rat liver is this enzyme. In [8] we reported the effects 
of simfibrate, a simple derivative of clofibrate, on the 
amount of the MI 80 000 polypeptide, and on the 
rate of the synthesis of this peptide in the liver, and 
showed that simfibrate stimulated the rate of biosyn- 
thesis of the polypeptide [8]. Here, the effects of 
clofibrate on the degradation rate of the hepatic 
peroxisome-associated M, 80 000 polypeptide is 
presented. 
2. Materials and methods 
2 .l . Materials 
D,L-[4,5-3H]Leucine (30 Ci/mmol) was obtained 
from Amersham RadioChemicals. L-Carnitine-HCl, 
acetyl-CoA, NAD, palmitoyl-CoA and CoA were 
ElsevierjNorth-Holland Biomedical Press 
obtained from Sigma Chemical Co. St Louis, MO 
DTNB (5,5’-dithio-bis(2-nitrobenzoic acid)) and DTT 
(dithiothreitol) were obtained from Wako Pure Chem- 
icals, Osaka. Other chemicals, all of reagent grade, 
were obtained from commercial sources. 
2.2. Animals and treatments 
Male mice of the ddY-strain (28-31 g) were used. 
Thirty animals were divided into 2 groups. After fast- 
ing overnight, mice were fed, ad lib. for 3 weeks on 
Oriental laboratory chow with and without 0.25% 
(w/w) clofibrate. After 3 weeks clofibrate-treatment, 
mice were injected intraperitoneally with 0.15 mCi 
D,L-[4,5-3H]leucine/1 0 g body wt, and then sacrificed 
at 0 (2 h), 2,4,6 and 8 days after this injection. After 
perfusing with ice-cold 0.25 M sucrose, the liver was 
removed and 10% (w/w) homogenate was prepared in 
0.25 M sucrose. 
Homogenates were used for assays of the peroxi- 
somal enzyme activities and for studies of decay of 
[3H]Leu in the peroxisomal protein component. 
2.3. Assay methods 
The enzyme activities of catalase, D-amino acid 
oxidase (DAAO) and urate oxidase were determined 
as in [9]. Unit enzyme activities of catalase and urate 
oxidase were defined as the amounts which caused a 
decrease of 1 unit AZ4 in 1 s and at AZ90 in 1 min at 
25”C, respectively. Monoamine oxidase activity was 
determined as in [lo] with modifications, using 
m-nitro benzylamine as substrate [ 111. One unit of 
the activity was defined as the amount of the enzyme 
which produced 1 nmol m-nitrobenzaldehyde from 
the substrate/min under the assay condition. This 
enzyme served as a marker enzyme for mitochondria. 
The activity of cyanide-insensitive FAOS was deter- 
mined spectrophotometrically from the palmitoyl- 
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CoA-dependent reduction of NAD at 340 nm in the 
presence of 1 mM KCN as in [3]. The activity of CAT 
(carnitine acetyltransferase) was determined spectro- 
photometrically using DTNB as in [ 121. These enzyme 
activities were assayed using the homogenate fraction. 
2.4. Studieson theperoxisomeproliferation-associated 
polypeptide 
The liver homogenate was centrifuged at 3300 X g 
for 10 min and the supernatant was recentrifuged at 
12 500 X g for 20 min at 4°C. The final pellet was 
suspended in 0.25 M sucrose-20 mM glycylglycine 
buffer (pH 7.4) (SC buffer) (equiv. 5 ml/g original 
tissue), which corresponds to ‘the light mitochondrial 
fraction (LM fraction)’ in [ 131. The separation of 
peroxisomes and mitochondria was carried out by 
sucrose density-gradient centrifugation of the fraction. 
Sucrose solutions were discontinuously layered from 
the bottom of 60 ml tubes: 8 ml 53.9% (w/w; density 
(d)=1.26g/m1);17m145.8%(d=1.215g/m1);15m1 
37.4% (d = 1.17 g/ml) and 10 ml 23.3% sucrose (d = 
1 .I0 g/ml) in 20 mM glycylglycine (pH 7.4). Centrifu- 
gation was carried out for 2.5 h at 24 000 rev./min at 
4°C using Hitachi RPS-25-2 rotor. Samples were col- 
lected in 4 ml fraction from the bottom of the tubes 
by a micropump. The peroxisome-rich fractions were 
collected and the protein content of the fraction was 
adjusted to 0.8 mg/ml after concentration with 
Amicon-5Minicon. 
The decay of [3H]Leu from protein components 
of the peroxisomes was as follows: The concentrated 
peroxisome fractions (0.1 ml) were subjected to 
sodium dodecylsulfate (SDS)-polyacrylamide gel elec- 
trophoresis 113. After electrophoresis the gels were 
stained with Coomassie brilliant blue and the band 
corresponding to the M, 80 000 polypeptide was 
separated off. The gel slices were put into 10 ml mini- 
vials solubilized in 0.5 ml NCS at 50°C overnight and 
counted in 5 ml toluene scintillator (DPO 3 g-di- 
methyl POPOP 75 mg/500 ml toluene). 
3. Results and discussion 
Certain hypolipidemic drugs, such as clofibrate, 
induce hepatomegaly and proliferation of hepatic 
peroxisomes in rat, accompanied by a significant 
increase in the activity of catalase, one of the marker 
enzymes of peroxisomes [ 14- 161. However, until 
now, reports of biochemical effects of these drugs on 
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Table 1 
Effects of clofibrate on the peroxisomal enzymes of the 
mouse liver 
Enzymes Activity (units/g liver) 
Control Clofibrate 
Catalase 25.5 + 3.4 35.1 + 2.8 P < 0.01 
DAAO 0.94 r 0.15 0.44 + 0.21 P < 0.01 
Uricase 4.11 f 0.48 4.32 5 0.71 ns. 
FAOS 0.36 f 0.12a 4.11 + 0.98a P < 0.01 
CAT 544 + 61b 8950 + 694b P < 0.01 
a Unit = pmol/min; b unit = nmol/min 
Values represent means r SD. Statistical evaluations were 
performed by Student’s r-test: n.s. means not significant 
(P > 0.05) 
hepatic peroxisomal enzymes of the mouse have been 
few. Table 1 shows the effects of clofibrate on some 
peroxisomal enzymes and on some enzymes related 
to fatty acid metabolism. The activities of cyanide- 
insensitive fatty acyl-CoA oxidation system (FAOS) 
and carnitine acetyltransferase (CAT) were markedly 
increased from 0.36 units/g liver to 4.1 units/g liver 
and from 544 units/g liver to 8950 units/g liver, res- 
pectively, in clofibrate-treated animals. This manner 
of alteration in the hepatic peroxisomal enzyme 
activities in the treated mouse is quite similar to that 
observed in the rat, suggesting that clofibrate may 
affect the metabolism of both animals in a similar 
manner. To isolate peroxisomes the ‘LM (light mito- 
chondrial) fraction obtained from the liver homog- 
enate was subjected to sucrose density gradient cen- 
trifugation. Fig.1 shows the typical pattern of the 
centrifugation. Catalase is the marker enzyme of 
peroxisomes and monoamine oxidase is of mitochon- 
dria. Peroxisomes and mitochondria were satisfactorily 
separated in accordance with those densities. Mono- 
amine oxidase activity in the peroxisomal fraction 
(fractions 2,3) was only 8.5% of the total activity. 
Fig.2 shows SDS-polyacrylamide gel electrophoretic 
analysis of the protein components of the peroxisomal 
fraction after sucrose density-gradient centrifugation 
of the LM fraction obtained from clofibrate-treated 
and control animals. The staining-density of the pro- 
tein band indicated by arrow was markedly higher 
than that of control, and the Mr was established to be 
-78 000-80 000 from its relative mobility to the 
marker proteins on SDS-polyacrylamide gel electro- 
phoresis. No other protein components seem to be 
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Fig.1. Sucrose density gradient centrifugation of the light mitochondrial fraction of the livers of the clofibrate-treated mouse. The 
light mitochondrial fraction (equiv. to 1 .O g liver) was layered on top of the gradients: (a), catalase; (a), monoamine oxidase; (o) 
protein. 
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Fig.2. Densitometry of stained gel. The gel was scanned by Shimazu CS-900 dual beam chromatoscanner as difference between 
550 nm (h,) and 490 nm (AR) after staining: (A) control; (B) clofibrate-treated. 
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Fig.3. Decay of the radioactivity of [3H]Leu from the perox- 
isomal MI 80 000 polypeptide. Mice fed a 0.25% clofibrate 
diet for 3 weeks were injected with [‘HI Leu and sacrificed 
at 0 (2 h), 2,4,6 and 8 days after. SDS-polyacrylamide gel 
electrophoresis of the peroxisomal fraction prepared from 
the LM fraction of the liver was performed as in section 2 
and the radioactivity in the band corresponding to peroxi- 
somal Mr 80 000 polypeptide was determined in a liquid 
scintillation counter. Each value plotted in the figure is the 
mean of 3 independent expt: (0) control; (0) clofibrate- 
treated. 
changed in amount. Fig.3 shows the time course of 
decay of the radioactivity of [3H]leucine in the 
peroxisome proliferation-associated M, 80 000 poly- 
peptide. At 0 time (= 2 h after injection), the radio- 
activity incorporated into the peptide of clofibrate- 
treated animal was increased by -3.8-fold. In course 
of time, the radioactivity in the peptide was gradually 
decreased and the half-life of disappearance of the 
radioactivity from the peptide was 38.4 h for treated 
and 32.4 h for control. These findings suggest hat, 
in the clofibrate animal, the increase in the amount of 
this peptide is primarily due to the enhancement of 
the biosynthesis of the peptide. This is supported by 
our previous finding that, in simfibrate-treated animals 
the initial incorporation rate of [3H]leucine into this 
polypeptide was -3-times higher at 2 h, compared 
with control animals [8]. Although, until now, intra- 
cellular localization of this Mr 80 000 polypeptide 
has not been established, the suggestion in [l] that 
this peptide is a component of the peroxisomal mem- 
brane is remarkably interesting. The characterization 
of clotibrate-inducible membrane protein of hepatic 
peroxisomes of rat is reported in [ 171 and the increased 
peptides shown to have IV, 40 000 and 80 000 [ 171. 
Further studies are required to elucidate whether 
the polypeptide is a structural protein component 
maintaining the granule structure or a functional 
protein such as an enzyme which contributes to the 
physiological functions of the granule. 
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